← All trials
NCT04713332
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 6, 2019
- Primary completion
- Mar 8, 2021
- Completion date
- May 8, 2021
- First posted
- Jan 19, 2021
- Last posted
- Feb 17, 2021
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of JordanLead sponsor
- University of JordanReponsible party - principal investigator
- Slovak Academy of SciencesCollaborator
- Al-Quds UniversityCollaborator
- Slovak Academy of SciencesStudy chair
- University of JordanStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.